Perspectives
Nature Reviews Drug Discovery 2, 919-928 (November 2003) | doi:10.1038/nrd1230
Science and society: Virtual drug discovery and development for neglected diseases through public–private partnerships
Solomon Nwaka1 & Robert G. Ridley2 About the authors
Abstract
In this article, we discuss the challenges, recent developments and new thinking on drug R&D for neglected diseases through public–private partnerships. The focus on virtual drug discovery and development as operationalized through these partnerships brings many advantages, as well as scientific and managerial challenges. Some are common to those faced by all drug R&D ventures. Others, for example the need for drugs with a very low cost of manufacture that are easy to use in resource-poor environments and an active engagement in disease-endemic countries, are unique to this novel paradigm.
Author affiliations
-
Solomon Nwaka is at the Medicines for Malaria Venture, Geneva, Switzerland
Email: nwakas@mmv.org -
Robert G. Ridley is at UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland.
Email: ridleyr@who.int
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated RESEARCH |
